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Abstract
Background: Recent studies suggested that insulin glargine use could be associated with increased risk of cancer. We
compared the incidence of cancer in new users of glargine versus new users of NPH in a longitudinal clinical cohort with
diabetes for up to 6 years.
Methods and Findings: From all patients who had been regularly followed at Massachusetts General Hospital from 1/01/
2005 to 12/31/2010, 3,680 patients who had a medication record for glargine or NPH usage were obtained from the
electronic medical record (EMR). From those we selected 539 new glargine users (age: 60.1613.6 years, BMI: 32.767.5 kg/
m
2) and 343 new NPH users (61.5614.1 years, 32.768.3 kg/m
2) who had no prevalent cancer during 19 months prior to
glargine or NPH initiation. All incident cancer cases were ascertained from the EMR requiring at least 2 ICD-9 codes within a
2 month period. Insulin exposure time and cumulative dose were validated. The statistical analysis compared the rates of
cancer in new glargine vs. new NPH users while on treatment, adjusted for the propensity to receive one or the other
insulin. There were 26 and 28 new cancer cases in new glargine and new NPH users for 1559 and 1126 person-years follow-
up, respectively. There were no differences in the propensity-adjusted clinical characteristics between groups. The adjusted
hazard ratio for the cancer incidence comparing glargine vs. NPH use was 0.65 (95% CI: 0.36–1.19).
Conclusions: Insulin glargine is not associated with development of cancers when compared with NPH in this longitudinal
and carefully retrieved EMR data.
Citation: Lim S, Stember KG, He W, Bianca PC, Yelibi C, et al. (2014) Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine
with New Users of NPH Insulin. PLoS ONE 9(10): e109433. doi:10.1371/journal.pone.0109433
Editor: Ramon Andrade de Mello, University of Algarve, Portugal
Received November 24, 2013; Accepted September 6, 2014; Published October 20, 2014
Copyright:  2014 Lim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was funded by Sanofi through a subcontract with the University of North Carolina at Chapel Hill. JBM is supported by K24 DK080140; TS is
supported by R01 AG023178. The funders played no role in the study design; collection, analysis, or interpretation of data; the writing of the report; or the
decision to submit the article for publication.
Competing Interests: The funding for this project was provided by Sanofi (Paris, France) through a subcontract with the University of North Carolina at Chapel
Hill. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed
products to declare.
* Email: jmeigs@partners.org
. These authors contributed equally to this work.
Introduction
Four studies investigating the association of glargine insulin
treatment with cancers, which were published in the journal
Diabetologia in 2009, created concern for both physicians and
patients with diabetes [1–4]. Since the publication of these studies,
many subsequent studies, meta-analyses, and editorials have
followed [5–12]. One study looking at the effects of glargine vs.
neutral protamine Hagedorn (NPH) on the progression of diabetic
retinopathy showed similar cancer incidence during 5 years
between the two treatment groups [9]. Another study based on the
French National Healthcare Insurance system database also
showed no excess risk of cancer in patients with type 2 diabetes
on insulin glargine compared with those on human insulin [8].
This study reported that the overall risk of cancer in patients
treated with insulin glargine was about half that of patients with
human insulin. Interestingly, another study from the Netherlands
found that insulin glargine use was associated with a 25% lower
risk of malignancies when compared with human insulin while a
58% increased risk in insulin glargine group was found for breast
cancer [7]. The Outcome Reduction with an Initial Glargine
Intervention (ORIGIN) trial showed exactly the same number of
cancer cases with glargine treatment vs. standard care without
insulin treatment over 6 years in subjects with prediabetes or early
diabetes [13]. More recently, data from French national health
insurance databases indicate that in a large cohort of more than
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increased risk of cancer observed in insulin glargine users
compared with other long-acting insulin users [14]. Another
recent study with more than 40,000 patients covered by the
Inovalon Medical Outcomes Research for Effectiveness and
Economics Registry showed that patients initiating insulin glargine
treatment did not show increased risk of cancer compared with
NPH users [15]. A caveat to these studies, however, is that they are
limited by relatively short follow-up work and consequently lack of
an accurate reflection of insulin prescription patterns.
In this study we reinvestigated the hypothesis that insulin
glargine has an impact on cancer incidence in patients with
diabetes via a new and improved approach that utilizes patient
electronic medical record (EMR) data. This approach was
designed to elucidate this relationship by improving on the
limitations of the previously mentioned conflicting studies,
including poorly defined drug and dose information, short study
duration, and a lack of control of potential confounding factors.
Subjects and Methods
2.1. Study population
The study was approved by the Institutional Review Boards of
the University of North Carolina at Chapel Hill and of the
Partners Healthcare System-MGH. The patient records/informa-
tion was anonymized and de-identified prior to analysis. Massa-
chusetts General Hospital (MGH) utilizes an EMR system that
allows for storage, retrieval, and modification of patient health
records. The EMR contains a plethora of health information for
patients including anthropometric parameters, lifestyle features,
diseases, laboratory results, and details of prescription of medica-
tion. From this database, we retrieved data for 20,087 patients
with diabetes aged at least 18 years old, and who were loyal to
MGH at 2005 and thereafter.
Patients were classified as loyal if they were connected either to
a specific attending primary care physician or to the practice
where they receive the majority of their care [16]. Loyal patients
with diabetes were defined as patients with diabetes who had at
least 2 consecutive years of loyal status. Among these loyal patients
with diabetes, 3,680 had at least one medication record for
glargine or NPH after 1/1/2005 and before 12/31/2010.
Of these patients, 2,285 had data from three 6-month periods
prior to the first record for glargine or NPH. In order to be
considered a new user, patients were required to have a 19 month
time period prior to glargine/NPH initiation where they did not
take any insulin (except a maximum of one prescription for short-
acting insulin). The 19-month time period was determined by
allowing for a one-month supply from the patient’s previous
insulin treatment, a six-month grace period, and the one-year
wash-out period. After excluding patients with an insulin
prescription during the 19 months prior to glargine or NPH
initiation and patients with any evidence of prevalent cancer
during this period, we found 578 new glargine users and 415 new
NPH users. From these patients, we selected 539 (glargine) and
343 (NPH) patients who had HbA1c levels at the time of
enrollment. This eligibility cohort algorithm is shown in Figure A
in File S1.
2.2. Measurement of outcomes
The primary outcome in this study was the development of any
cancer excluding non-melanoma skin cancer. We excluded cases
of non-melanoma skin cancer in the analysis as it is not likely to be
influenced by insulin treatment biologically [14,15]. The only
carcinoma in situ (CIS) that were included in the primary
outcome were cases of CIS breast cancer (a complete list of
ICD-9 cancer codes is included in Table A in File S1).
To identify incident cancer cases after initiation of glargine or
NPH insulin, we abstracted ICD-9 cancer codes from the EMR.
To ensure that patients were correctly allotted into either the
cancer or no cancer group, we used modified criteria as proposed
by Setoguchi et al., which require at least 2 ICD-9 cancer codes on
two different dates within a 2 month period to diagnose cancer
[17]. Requiring two codes significantly reduces the number of
cases that are identified in error (false positives). As a validation of
the use of the Setoguchi et al. criteria to identify cancer cases in
our database, we randomly selected 120 patients with diabetes
who were diagnosed with one of 5 cancers (breast, prostate, colon,
pancreas, bladder, and kidney cancers) using the modified
Setoguchi criteria, and 20 patients with diabetes but without
cancer. We then manually assessed the EMR for each patient to
determine their cancer status. If patients did in fact have a specific
cancer, a diagnosis date was recorded. In these two groups of
patients with and without cancer, we found 99% sensitivity and
95% specificity in the diagnosis of cancer using the Setoguchi
criteria as compared to our manually assessed records.
2.3. Measurement of exposure
Insulin use and dose. From the EMR database we collected
data for glargine and NPH use that included dose as well as start
and end date of prescription. Parallel use of other insulin was also
investigated. The effect of cumulative insulin dose was addressed
by calculating the cumulative insulin dose as of every new insulin
record for glargine or NPH and categorizing patients into
mutually exclusive categories of cumulative dose (e.g., 02,10
kU, 102,20 kU, 202,50 kU, $50 kU). Cumulative dose was
based exclusively on the medication records for either glargine or
NPH (whichever long-acting insulin was initiated); dose of short-
acting insulin was not included. Cumulative dose was calculated
until a patient stopped taking long-acting insulin, augmented with
different long-acting insulin, switched to other long-acting insulin
or the study ended (whichever came first). We also gathered other
diabetes medication information including name of drug and dose,
and date that it was prescribed from the EMR data.
Validation of all other major clinical
exposures. Anthropometric and biochemical parameters such
as body mass index (BMI), blood pressures, serum hemoglobin,
liver enzyme activities, serum creatinine, fasting glucose, glycosy-
lated hemoglobin (HbA1c), and lipid profiles were measured
during usual clinical care. All covariates such as duration of
diabetes, smoking status, comorbidity, and medication were
defined based on data from the one year period prior to the start
date of NPH or glargine. The only exception was BMI; in this
case, the latest available value prior to or on the start date of NPH
or glargine was used when available. In 3.4% of patients, the
earliest BMI value within the two years after the start of NPH or
glargine was used. Medical information including frequency of
clinic visit, number of hospitalizations for any reason, and total
number of days in the hospital for any reason, was also obtained
from the EMR database.
We used Natural Language Processing (NLP) to gather smoking
information from the discharge summaries in the EMR [18]. Only
NLP records prior to the start date of NPH or glargine were used
in order to assess the smoking status of a new user before the start
date of diabetes treatment. We summarized the data so that each
patient had a smoking status for each calendar year. We
considered a patient ‘current smoker’ if he or she had a current
smoking status in the glargine or NPH start date year. Patients
Cancer Incidence Glargine vs. NPH
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Unadjusted Values Propensity Score Weighted Values
Demographic Characteristic Glargine N=539 NPH N=343 Glargine NPH
Age, mean (SD) 60.1 (13.6) 61.5 (14.1) 60.3 (14.0) 59.9 (14.8)
Duration of diabetes (years), mean (SD) 8.2 (5.7) 8.2 (5.8) 8.3 (5.6) 8.1 (5.8)
Baseline BMI (kg/m
2), mean (SD) 32.7 (7.5) 32.7 (8.3) 32.5 (7.6) 32.2 (8.1)
HbA1c category, n (%)
#7.5% or 58 mmol/mol 103 (19.1) 88 (26.0) 142 (26.1) 88 (26.0)
7.5% or 58 mmol/mol,,#8.6% or 70 mmol/mol 158 (29.3) 89 (26.4) 150 (27.6) 89 (26.4)
8.6% or 70 mmol/mol,,#10.2% or 88 mmol/mol 173 (32.1) 90 (26.7) 145 (26.7) 90 (26.7)
.10.2% or 88 mmol/mol 105 (19.5) 70 (20.9) 106 (19.6) 70 (20.9)
Women, n (%) 261 (48.4) 165 (49.1) 267 (49.2) 165 (49.1)
White, n (%) 382 (70.9) 257 (74.9) 393 (72.3) 246 (73.0)
Black, n (%) 36 (6.7) 28 (8.2) 38 (7.0) 22 (6.5)
Smoking category, n (%)
Never smoker 205 (38.0) 112 (32.7) 192 (35.4) 128 (38.1)
Past smoker 163 (30.2) 128 (37.3) 183 (33.6) 106 (31.3)
Current smoker 171 (31.7) 103 (30.0) 169 (31.0) 103 (30.6)
Year of cohort entry, n (%)
2005 47 (8.7) 58 (16.9) 68 (12.5) 42 (12.6)
2006 87 (16.1) 80 (23.3) 99 (18.3) 68 (20.2)
2007 123 (22.8) 87 (25.4) 132 (24.4) 76 (22.5)
2008 161 (29.9) 66 (19.2) 138 (25.4) 90 (26.7)
2009 121 (22.4) 52 (15.2) 106 (19.5) 61 (18.1)
Comorbidity
Pulmonary disease, n (%) 73 (13.5) 75 (21.9) 89 (16.3) 55 (16.3)
Congestive heart failure, n (%) 62 (11.5) 68 (19.8) 82 (15.1) 51 (15.2)
Diabetic retinopathy, n (%) 20 (3.7) 20 (5.8) 24 (4.4) 16 (4.6)
Diabetic nephropathy, n (%) 76 (14.1) 69 (20.1) 96 (17.7) 56 (16.6)
Diabetic neuropathy, n (%) 45 (8.3) 60 (17.5) 64 (11.8) 41 (12.1)
Medication
Metformin, n (%) 385 (71.4) 192 (56.0) 360 (66.3) 224 (66.6)
Thiazolidinediones, n (%) 159 (29.5) 59 (17.2) 128 (23.6) 73 (21.7)
Sulfonylureas, n (%) 385 (71.4) 169 (49.3) 337 (62.0) 199 (59.2)
Other hypoglycemic agents, n (%) 40 (7.4) 17 (5.0) 33 (6.0) 15 (4.4)
Statins, n (%) 393 (72.9) 247 (72.0) 387 (71.3) 234 (69.4)
Bile acid medications, n (%) 8 (1.5) 3 (0.9) 6 (1.1) 3 (0.8)
Fibrates, n (%) 66 (12.2) 33 (9.6) 61 (11.2) 32 (9.5)
Niacin, n (%) 11 (2.0) 6 (1.7) 14 (2.6) 9 (2.7)
Other lipid-lowering medications, n (%) 40 (7.4) 18 (5.2) 39 (7.2) 22 (6.6)
Testosterone, n (%) 5 (0.9) 1 (0.3) 3 (0.6) 1 (0.3)
Estrogen, n (%) 11 (2.0) 4 (1.2) 8 (1.6) 3 (1.0)
Estradiol, n (%) 13 (2.4) 8 (2.3) 12 (2.2) 6 (1.8)
Oral contraceptives, n (%) 16 (3.0) 11 (3.2) 16 (2.9) 8 (2.4)
Progesterone/Progestin, n (%) 13 (2.4) 12 (3.5) 14 (2.5) 8 (2.3)
Cardiac glycosides, n (%) 27 (5.0) 28 (8.2) 31 (5.8) 19 (5.7)
ACE inhibitors/ARBs, n (%) 410 (76.1) 256 (74.6) 406 (74.6) 245 (72.8)
Diuretics (loop), n (%) 105 (19.5) 102 (29.7) 129 (23.8) 77 (22.8)
Diuretics (non-loop), n (%) 211 (39.1) 175 (51.0) 236 (43.5) 143 (42.4)
Anticholinergics, n (%) 41 (7.6) 43 (12.5) 50 (9.2) 32 (9.6)
Beta 2 agonist, n (%) 125 (23.2) 96 (28.0) 132 (24.3) 80 (23.7)
Cancer Incidence Glargine vs. NPH
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glargine or NPH were considered ‘past smokers’.
2.4. Statistical analysis
First, we compared clinical characteristics including age, sex,
duration of diabetes, BMI, smoking status, medications, screening
tests for cancer, and the number of physician visit between new
glargine users and new NPH users (Table 1). To adjust for
potential confounding due to channeling between the insulin
glargine and NPH, the propensity score for glargine initiation was
estimated for all variables using logistic regression models [19].
Briefly, the stabilized inverse probability of treatment weights was
calculated. We then applied the weights and checked that the
treatment groups were balanced in terms of the covariates in the
weighted pseudo-population (Table 1).
We used an intent-to-treat approach for the primary analysis of
the relationship between insulin use and cancer incidence. We
tested incidence rates of cancers in new glargine users versus new
NPH users from the time of drug initiation until the time point of:
(1) diagnosis of any cancer (except non-melanoma skin cancer), (2)
death, (3) termination of health care at MGH (defined as one year
past the last available visit date in the database), or (4) the end of
the study (December 31, 2010); whichever came first. The
association between insulin use and cancer incidence was analyzed
in the weighted pseudo-population using Cox proportional hazard
models.
For further analysis, we included cumulative dose as a time-
varying covariate in the Cox proportional hazards model. With
every new record for glargine or NPH (whichever treatment was
initiated), cumulative dose was calculated and patients were
categorized into mutually exclusive categories of cumulative dose
(0210 kU, $10220 kU, $20250 kU, $50 kU etc). Time at risk
for incident cancer began once a patient reached the correspond-
ing cumulative dose and ended once a patient reached the next
cumulative dose level. If a patient had a cancer event, it was
counted within the dose category when it occurred. All data were
analyzed using SAS Version 9.2 (SAS, Cary, NC, USA). The
nominal level of significance for all analyses was P,0.05.
Results
Table 1 shows baseline characteristics of new glargine and new
NPH users. After propensity score implementation, all demo-
graphic variables were balanced across treatment cohorts. The
current smoker at the baseline was about one third in both groups.
Co-morbid conditions including diabetic complications were also
not statistically different between two groups after propensity score
implementation. Similarly, oral antidiabetic medications, particu-
larly metformin, were comparable between glargine users and
Table 1. Cont.
Unadjusted Values Propensity Score Weighted Values
Demographic Characteristic Glargine N=539 NPH N=343 Glargine NPH
Theophylline, n (%) 14 (2.6) 13 (3.8) 18 (3.3) 11 (3.2)
Corticosteroid, n (%) 113 (21.0) 103 (30.0) 132 (24.2) 82 (24.3)
Anti-depressants, n (%) 219 (40.6) 130 (37.9) 220 (40.6) 135 (40.0)
Beta blockers, n (%) 267 (49.5) 177 (51.6) 276 (50.8) 164 (48.8)
Calcium channel blockers, n (%) 126 (23.4) 113 (32.9) 145 (26.8) 91 (27.2)
Medical history
Number of Patients with each of the Following Tests, n (%)
Colonoscopy 59 (10.9) 33 (9.6) 59 (10.8) 39 (11.6)
Pap Smear 76 (14.1) 53 (15.5) 84 (15.5) 51 (15.2)
PSA Test 124 (23.0) 70 (20.4) 124 (22.9) 79 (23.6)
Mammogram 132 (24.5) 76 (22.2) 127 (23.5) 71 (21.1)
ECG 268 (49.7) 208 (60.6) 297 (54.6) 184 (54.7)
Cholesterol Test 490 (90.9) 313 (91.3) 495 (91.2) 297 (88.3)
Flu vaccine 276 (51.2) 163 (47.5) 266 (49.0) 177 (52.6)
Fecal occult blood test 69 (12.8) 48 (14.0) 74 (13.7) 45 (13.3)
Primary care physician visits, n (%)
0 167 (31.0) 118 (34.4) 174 (32.0) 103 (30.6)
1–3 95 (17.6) 84 (24.5) 115 (21.2) 71 (21.1)
4–6 167 (31.0) 82 (23.9) 147 (27.1) 91 (27.0)
.6 110 (20.4) 59 (17.2) 107 (19.7) 72 (21.4)
Diabetes center physician visits, n (%)
0 485 (90.0) 253 (73.8) 454 (83.7) 280 (83.0)
1–3 34 (6.3) 52 (15.2) 54 (10.0) 35 (10.5)
4–6 15 (2.8) 30 (8.7) 25 (4.7) 17 (5.0)
.6 5 (0.9) 8 (2.3) 9 (1.7) 5 (1.4)
Note: Only patients with nonmissing values for all covariates are included. All variables were included in the logistic regression for propensity score.
doi:10.1371/journal.pone.0109433.t001
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in the number of patients who received cancer screening tests in
either crude or propensity score implemented comparisons. In
comparison of health care utilization 1 year prior to index
prescription, the total number of primary care center visits and
diabetes center visits were not different between glargine users and
NPH users (Table 1). Thus, after adjustment for the propensity to
have been treated with glargine versus NPH, there was no
difference in rates or proportions of important clinical character-
istics related with cancers comparing new glargine users with new
NPH users.
The range of follow-up was 1–71 months and the median
follow-up was 37.2 months (34.7 and 39.4 months in glargine and
NPH group, respectively). Twenty three patients died during
follow-up. As primary outcome, we found 54 incident cancer cases
occurring after the new use of insulin in intent-to-treat analysis
(Table 2). Of these cases, 26 events occurred in the glargine
group and 28 occurred in the NPH group. Breast and prostate
cancers were most common and colon, pancreas, lung, and kidney
cancers followed next (Table A in File S1). After accounting for
potential clinical confounders, the hazard ratio for incidence
cancer comparing new glargine with new NPH users was 0.65
(95% confidence interval 0.36, 1.19), indicating no increased risk
of cancer in new glargine users compared with new NPH users.
There is a possibility that diagnosis of cancer during the first
year of follow-up may not be associated with insulin treatment.
Among 56 patients who developed cancer during follow-up
period, 8 in the glargine group and 8 in the NPH group developed
cancer within the first year of treatment. There was no significant
difference in risk of cancer incidence between the insulin glargine
and NPH use excluding these cases. The cancer free survival
curves between new users of insulin glargine and new users of
NPH is shown in Figure 1.
During follow-up, 5.4% were switched to other long-acting
insulin, and 12.5% stopped taking long-acting insulin before the
study ended. Cumulative insulin dose was calculated until these
points. The data with cumulative insulin dose was analyzed in
Table 3 (As-Treated Analysis). Since this needed to be performed
as an as-treated analysis, the study subjects (n=772) in Table 3 is
slightly fewer than that (n=882) in Table 2, where everybody is
included. The numbers of subjects in Table 3 reflect the number
of participants in each cumulative dose category: i.e., every patient
is counted in the first dose category (n=503 in glargine and
n=269 in NPH group) because everyone in this analysis had some
exposure to drug. If these patients experience a cancer event
before they reached a cumulative dose of 10 K, then their cancer
event is counted in this dose category as well. The numbers for the
second dose category (n=391 in glargine and n=210 in NPH
group) reflect the number of patients who had a cumulative dose of
at least 10 K; these 601 patients are a subset of the 772 patients
who are in the first (0–10 K) dose category. In the Cox
proportional hazards models adjusted for age and gender, no
association of increased cancer risk with increased insulin dose was
found (Table 3).
Discussion
In this study of new insulin users (average age, 60 years; average
duration of diabetes, 8 years), treatment with glargine insulin did
not increase incidence of cancers when compared with NPH users
after adjusting for baseline cancer risk factors including BMI and
smoking status. Moreover, further adjustment of insulin dose did
not affect this neutral effect of glargine insulin on incidence of
cancers.
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created such a concern for cancer risk with insulin glargine use [1–
4], several new studies have been published in regard to this issue,
which are still inconclusive and have their own limitations
[5,7,8,10–12]. In a retrospective cohort study of patients with
type 2 diabetes registered with the US Medicare, the data on
important clinical risk factors for cancer including smoking status
and obesity degree were not adjusted for [10]. In the study using
the French National Healthcare Insurance system database,
smoking status was not accounted for [8]. Another study using
pharmacy dispensing data in the Netherlands had a likelihood of
allocation bias and lower adherence to insulin glargine [7]. More
recently, two large cohort studies from the French health
insurance information system and the Inovalon Medical Out-
comes Research for Effectiveness and Economics Registry showed
no increased risk of any cancer in insulin glargine users compared
with other long-acting insulin users [14,15].
In contrast to these previous studies, we retrieved an array of
relevant clinical and biochemical information such as baseline
BMI, smoking status, concomitant medications, and cancer
screening from the EMR, and performed the final regression
model adjusted with this complete data. For smoking status in
particular, we defined smoking status using the Natural Language
Processing from the EMR discharge summaries [18]. It is
important to point out that none of these variables were observed
to confound the association between insulin use and cancer
incidence.
For this study, we started with more than 20,000 patients and
after careful selection process we only had 54 cancers cases. This
suggests that with careful selection of patients, only a very small
proportion are valid for looking at specific interactions like the one
between glargine dose and cancer incidence. This also indicates
importance of meticulous selection and adjustments to attain
decisive answer to this unclear interaction.
More recently, the ORIGIN study showed that there was no
increase of cancer incidence with glargine treatment over 6 years
in subjects with prediabetes or early diabetes when compared to
standard-care [13]. But the ORIGIN study population consisted of
people who would not normally be prescribed insulin and the
study had no active comparator such as NPH insulin. This may
explain the significant differences in the baseline characteristics
between ORIGIN and our study including comorbidities, diabetic
complications, and other medications [5]. Indeed, there is the
possibility that physicians tend to start or switch to insulin glargine
in patients who are already more prone to developing cancers [6].
Patients who are generally less healthy are more likely to be
prescribed easily administered daily insulin glargine than other
types of insulin; this allocation bias is one of the limitations of
previous studies [1,6,20,21].
Our work yielded contrasting results using an active comparator
study design. That is, the study mimics a treatment decision
between two long acting insulins rather than comparing treated
with untreated patients. Even hat physicians do not channel
specific patients based on their BMI, smoking status, nor HbA1c
preferentially to any of the long acting insulins compared here.
Several studies have shown a correlation between glargine dose
and cancer risk [1,22]. In order to investigate this relationship, we
prospectively categorized cumulative insulin dose and found that
Figure 1. Cancer free survival curves in new glargine and NPH insulin users.
doi:10.1371/journal.pone.0109433.g001
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glargine insulin on the incidence of cancer.
In this context, we had several advantages in the study design.
We utilized new NPH users as an active comparator and there was
no significant difference between groups with regard to diabetes
severity and other potential cancer risks. We also adopted
sophisticated methodology to perform a retrospective longitudinal
study using EMR data. We applied strict and innovative criteria to
obtain new users of glargine and NPH without prevalent cancer
during 19 months prior to insulin initiation. This latent period
helped us exclude indolent cancer cases in which cancer might be
already present before diagnosis. Using this process, new glargine
or NPH users without indolent cancers could be selected precisely,
which suggests that these methods can be used as an example for
future studies attempting to utilize EMR data. We also accounted
for clinical visits and hospitalizations, which might have led to
higher chance of cancer detection. We believe that the method
used in this study can act as a potential model for others who may
try to use EMR data for pharmacoepidemiologic study.
There are also several limitations of this study. First, the follow-
up duration was not long enough to estimate the risk of some
cancers although our average length of follow-up is comparable to
previous studies [22]. Moreover, the number of study subjects was
no as substantial as that of recent studies [14,15]. In addition, due
to the limited number of cancer cases, we could not evaluate
individual cancer risk. However, from a clinical aspect, arguably
patients do not really care what cancer they develop among those
ascertained. Second, there is a possibility that some patients can be
treated in other hospitals. But the recruitment strategy of selecting
loyal patients is likely to reduce this chance. Fourth, the
compliance of insulin medication was not examined.
In conclusion, no cancer signal with insulin glargine was found
in this carefully characterized clinical cohort with diabetes. While
our study is limited in size, we avoided potential for major
distortions (or bias) by implementing a new user, active
comparator study design. Our study thus adds to the evidence
that insulin glargine does not increase the risk for any cancer
outcomes when compared with its main treatment alternative,
NPH insulin.
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